Phagenesis Ltd. Company Research Report

Company Overview

Name: Phagenesis Ltd.

Mission: Phagenesis is committed to transforming the treatment of dysphagia through innovative, non-surgical therapies that enhance patient care and quality of life.

Founded: 2007

Founders: Dr. Conor Mulrooney and Professor Shaheen Hamdy from the University of Manchester.

Key People:

Chad Hoskins: Chief Executive Officer (CEO), appointed September 2024.

Oern Stuge, MD: Chairman of the Board of Directors.

Scott Grant: Vice President Therapy Development US.

Andre Nel: Chief Financial Officer.

Headquarters: Unit 18 Enterprise House, Manchester Science Park, Manchester, M15 6SE, UK.

Number of Employees: 11-50 employees.

Revenue: No information is available.

What is the company known for: Phagenesis is known for developing Phagenyx®, a first-of-its-kind neurostimulation system to restore swallowing control in patients with severe dysphagia (difficulty swallowing).

Products

Phagenyx® Neurostimulation System

Description: A revolutionary medical device that uses Pharyngeal Electrical Stimulation (PES) to treat dysphagia by enhancing neurorehabilitation and reorganization of swallowing control.

Key Features:

Non-surgical and implant-free therapy: Utilizes non-invasive PES for restoring swallowing function.

Personalized levels of stimulation: Customized delivery based on individual patient needs.

Dual-Function Catheter: Facilitates both feeding and stimulation delivery.

Simple Integration: Designed for easy incorporation into existing healthcare systems.

Extensive Clinical Evidence: Backed by over a decade of clinical use in Europe with multiple randomized controlled trials and publications.

Recent Developments

New CEO Appointment:

In September 2024, Chad Hoskins was appointed as the Chief Executive Officer. He is expected to leverage his extensive experience in scaling innovative medical technologies and expanding commercial growth in the US.

Funding:

In March 2024, Phagenesis closed a $42 million Series D financing round, led by EQT Life Sciences and Sectoral Asset Management, with new investors including British Patient Capital, Northern Gritstone, and Aphelion. The funds are intended to bolster commercialization efforts in the US and Europe.

Market Expansion:

Phagenesis is actively focusing on accelerating the adaptation of Phagenyx® to treat more patients across the US and Europe. Several healthcare facilities in these regions have already begun using the system.

Clinical Integration and User Engagement:

The company has been engaging with healthcare providers and hosting user group meetings and symposiums, such as the first German User Group Meeting and the Austrian User Group Meeting, to facilitate knowledge sharing and enhance practical applications of Pharyngeal Electrical Stimulation (PES) therapy.

Research and Evidence:

Phagenesis continues to support and promote new research with evidence of improved clinical outcomes for dysphagia patients, underscoring the safe, effective, and economic advantages of the Phagenyx® system.

Conclusion

Phagenesis Ltd. stands as a leader in the medical device industry with its pioneering neurostimulation technology aimed at treating dysphagia. With the addition of an experienced CEO, successful fundraising, and a strategic focus on expanding its presence in the US and European markets, Phagenesis is well-positioned to significantly impact the treatment landscape for swallowing disorders.